Klövern AB (publ)
15.1.2021 13:32:13 CET | Globenewswire | Press release
Nykredit Bank A/S has through an agreement dated on 14 January 2021 acceded to Klövern AB (publ)’s unsecured MTN program (the ”MTN Program
”) as dealer in accordance with the general terms and conditions of the MTN Program originally dated on 4 February 2020 and as amended on 6 October 2020.
The other dealers under the MTN Program are Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank Abp and Swedbank AB (publ).
Further information about the MTN Program can be found on Klövern’s website (www.klovern.se
).
Klövern AB (publ)
For additional information, please contact:
Jens Andersson, Head of Finance, +46 (0)76-855 67 02, jens.andersson@klovern.se
Rutger Arnhult, CEO, +46 (0)70-458 24 70, rutger.arnhult@klovern.se
Lars Norrby, IR, +46 (0)76-777 38 00, lars.norrby@klovern.se
Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se.
Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Phone: +46 (0)10-482 70 00. E-mail: info@klovern.se
.
This is a translation of the original Swedish language press release. In the event of discrepancies, the original Swedish wording shall prevail.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
